GET DAILY SIGNALSOxford Nanopore (ONT) Delivers +12.3% Revenue Growth and +400 bps Gross Margin Expansion
Key Takeaways
- Revenue rose 12.3% at constant currency (CC) to £116.7 million, but came in below management's earlier expectations as China and the Middle East weighed on performance.
- Gross margin expanded by 400 basis points (bps) to 62.2%, while the adjusted EBITDA loss narrowed sharply to £22.1 million from £48.3 million a year earlier.
- Growth was strongest in applied markets, with Clinical revenue up 35.4% and BioPharma up 25.0%, while Research grew a more modest 5.4%.
- The company reaffirmed its target of adjusted EBITDA breakeven in FY27 and positive free cash flow in FY28.
- Full-year 2026 guidance was maintained at 16–20% constant-currency revenue growth, excluding a $20 million non-recurring licensing fee.
Why These Results Matter
Oxford Nanopore's interim results matter because they test whether the company can keep growing while closing the gap to profitability. For the six months ended 30 June 2026, the narrative shifted from pure revenue momentum to operating leverage, with gross margin up 400 bps and adjusted EBITDA losses more than halving. Investors are watching closely because the company is still loss-making and has pledged to reach adjusted EBITDA breakeven in FY27 and positive free cash flow in FY28. Regional headwinds, particularly a roughly 16% decline in China revenue, added a layer of caution to an otherwise improving cost and margin story. I also checked this using Tickeron’s AI Screener to see how ONT compares to others in the industry.
The First-Half Numbers in Detail
Revenue for the first half reached £116.7 million, up 12.3% at constant currency and 10.5% on a reported basis, but below management's earlier expectations. Growth was led by EMEAI (Europe, Middle East, Africa, and India), up 23.8% at constant currency, and the Americas (AMR), up 12.5%. Asia-Pacific (APAC) declined 8.4%, driven by a 15.7% fall in China linked to enhanced export-control restrictions and changes to commercial operations.
Gross margin rose 400 bps to 62.2%, while adjusted operating costs fell 6.9% year over year. As a result, the adjusted EBITDA loss narrowed to £22.1 million from £48.3 million, and the loss for the period fell to £48.0 million from £71.8 million. By end market, Clinical revenue grew 35.4%, BioPharma 25.0%, Industrial 6.2%, and Research 5.4%. Cash and liquid investments stood at £234.5 million at 30 June 2026, down from £302.8 million at the end of 2025, partly reflecting a seasonal working-capital outflow.
How the Market Responded
Shares rose sharply on results day, with media reports indicating a gain of roughly 16% as investors focused on the margin improvement and narrowing losses rather than the softer top-line result. The market appeared to reward evidence that restructuring and efficiency measures are translating into operating leverage. Sentiment heading into the report had been cautious given the China and Middle East headwinds, but the combination of a 400 bps gross-margin gain, a halving of the adjusted EBITDA loss, and reaffirmed profitability targets helped reassure investors about the company's path to breakeven.
Looking Ahead
Management maintained its 2026 guidance, targeting constant-currency revenue growth of 16–20% excluding a $20 million non-recurring licensing fee from a newly announced cross-licensing agreement with a global diagnostics company. Including that fee, growth is expected to reach roughly 23–27%. The company also expects gross margin of approximately 62%, or about 64% including the licensing income, and now guides adjusted operating costs to decline 2% to remain flat, an improvement from the prior range of 0–5% growth.
Investors should monitor whether revenue reaccelerates in the second half as new device placements convert into consumable demand and as comparisons ease against ended research programs. The second-half recognition of the $20 million licensing fee at 100% gross margin should provide a one-off boost, but the longer-term royalty stream tied to the agreement remains the more meaningful driver and is not included in guidance.
Beyond 2026, the company reaffirmed adjusted EBITDA breakeven in FY27 and positive free cash flow in FY28, alongside a new target of more than $700 million in revenue by 2030 with an adjusted EBITDA margin above 15%. Key factors to watch include the pace of recovery in China, execution on clinical and biopharma adoption, gross-margin durability, and continued cost discipline as the business scales toward profitability.
AI Tools in My Research Process
I’ve found Tickeron’s AI Screener useful when evaluating names like ONT alongside peers. It lets me quickly filter for technical patterns, fundamentals, and AI-driven signals to spot comparable opportunities in the sector without manual effort.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ONT's RSI Indicator recovers from oversold territory
The RSI Oscillator for ONT moved out of oversold territory on October 05, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 35 similar instances when the indicator left oversold territory. In 33 of the 35 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on ONT as a result. In 68 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for ONT just turned positive on October 15, 2026. Looking at past instances where ONT's MACD turned positive, the stock continued to rise in 39 of 47 cases over the following month. The odds of a continued upward trend are 83%.
ONT moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +6.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where ONT advanced for three days, in 230 of 299 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ONT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
ONT broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ONT entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.280) is normal, around the industry mean (47.547). P/E Ratio (-50.613) is within average values for comparable stocks, (56.457). ONT's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.132). Dividend Yield (0.000) settles around the average of (0.016) among similar stocks. P/S Ratio (0.808) is also within normal values, averaging (72.867).
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. ONT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ONT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 76, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in the provision of air measurement and environmental laboratory services
Industry EnvironmentalServices
Advertisement